Core Viewpoint - eToro Group Ltd. has launched a new shareholder engagement initiative in partnership with Stockperks, emphasizing the importance of retail investors as partners in creating a more inclusive financial system [1][5]. Company Overview - eToro was founded in 2007 with the mission to make investing accessible to everyone, focusing on community-driven approaches that promote social and collaborative investing experiences [2][7]. - The platform has grown to 40 million registered users across 75 countries, offering a range of traditional and innovative assets for investment [7]. Shareholder Engagement Initiative - The new initiative aims to deepen engagement with eligible eToro shareholders through educational content, events, and direct interactions with company leaders and market experts [4][3]. - This initiative is part of eToro's commitment to being the voice of retail investors and enhancing relationships with its community [3][5]. Educational and Community Benefits - The initiative will provide shareholders with exclusive educational benefits and insights, reinforcing eToro's belief in shared knowledge and collective success [5][4]. - eToro's CEO highlighted that the initiative is about strengthening community ties and enhancing participation in global markets [5]. Partnership with Stockperks - Stockperks is described as an innovative shareholder loyalty marketplace that connects retail investors with companies, allowing for year-round engagement and rewards [8]. - The partnership is expected to enhance eToro's ability to engage with retail investors and provide them with valuable insights and educational resources [5][8].

Core Insights - Turn Therapeutics has launched a comprehensive communications initiative aimed at enhancing engagement with shareholders and the healthcare community, which includes a recurring webinar series and a Founder Blog by CEO Bradley Burnam [1][2]. Company Overview - Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases. The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [3]. Communications Initiative - The initiative includes a webinar series that will cover ongoing programs, strategic milestones, and upcoming developments, with the first session scheduled for October 22, 2025, at 2:00 PM ET [2][3]. - The Founder Blog will provide updates on company progress, research insights, and perspectives on growth and innovation, with further details to be announced [2]. Commitment to Public Health - Turn Therapeutics is also pursuing global health initiatives, particularly in thermostable vaccine delivery, aimed at serving underserved areas worldwide, reflecting the company's commitment to public health innovation [3].